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Abstract
Introduction: Venous thromboembolism is a multifactorial disease defined by multiple interactions
between genetic and environmental components. It is managed by oral anticoagulation with warfarin
sodium (Coumadin), a drug that targets the vitamin K epoxide reductase to prevent the recycling of
vitamin K epoxide to the reduced form of vitamin K. The reduced form of vitamin K is an essential
cofactor in the formation of active clotting factors II, VII, IX, X and regulatory factors protein C, and
cofactor protein S through gamma-glutamyl carboxylation. The duration of Coumadin treatment,
three to six months or life-long, should be based on the individual risk for recurrent deep vein
thrombosis and on the associated increased risk for bleeding complications.
Case Presentation: A previously healthy 50-year-old white male developed a deep vein
thrombosis consequent to surgical placement of a titanium rod to correct a fracture of the femur
and he was maintained for over a year on daily oral doses of Coumadin 9 mg and aspirin 325 mg.
When he began to bruise spontaneously with multiple large hematomas appearing without
provocation, he requested that his primary care physician reconsider the anticoagulation. Because of
his age, sex, and the possibility of an inherited or acquired anticoagulant protein deficiency he was
maintained on Coumadin and a thrombophilia work up was ordered. Test results were interpreted as
deficiencies in both protein C and protein S and he was instructed that life-long therapy with
Coumadin was necessary. Is this a correct evaluation by his primary care physician?
Conclusion: This case illustrates that Coumadin, a vitamin K agonist, was exerting a therapeutically
acceptable negative influence on plasma activity levels of vitamin K-dependent protein C and
protein S. Relying on the outcome of a thrombophilia work-up for a decision to maintain or cease
Coumadin treatment of patients at risk for recurrent deep vein thrombosis has pitfalls that can be
avoided. The use of real-time B-mode venous ultrasonography to verify complete restoration of
venous flow before ceasing Coumadin treatment is not always considered in the long-term
management of a patient with a first thrombosis, despite the well documented significant risk of deep
vein thrombosis recurrence associated with an unresolved thrombosis.
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In the mid 20
th century, Dr Paul Link noted that cows
eating spoiled clover died of hemorrhage. The substance in
spoiled clover was purified and was found to be a racemic
mixture (R and S isomers) of the anticoagulant drug (3-(a-
acetonylbenzyl)-4-hydroxycoumarin) warfarin. The action
of warfarin S isomer on VKORC1 prevents vitamin K1
from participating in a post-translational reaction to
carboxylate glutamate residues on inactive vitamin
K-dependent coagulation factors (factors II, VII, IX, X,
and protein C and protein S). This carboxylation reaction
is necessaryto produce active vitamin K-dependent factors.
Warfarin R and S isomers are metabolized in the liver
through distinct pathways. The rate of oxidative meta-
bolism of the more active warfarin S isomer is affected by
the cytochrome P450 CYP2C9 hydrolase activity, [1] and
polymorphisms in the genes encoding this enzyme
influence vitamin K1 levels and the degree of blood
fluidity in individuals anticoagulated with warfarin. In
addition to genetic factors, diet, drugs, and various disease
states influence the agonist effect of warfarin on vitamin K.
Theanticoagulantactivityofwarfarinsodium(Coumadin)
is dependent on absorption from the gut, with levels in the
blood peaking about 90 minutes after drug administra-
tion, and a plasma half-life of 36 to 42 hours. Over 97% of
circulating Coumadin is bound to albumin, with only the
small fraction of unbound Coumadin that is biologically
active. Coumadin does not act by directly dissolving
thrombi, but by targeting the vitamin K epoxide reductase
(VKORC1), Coumadin reduces blood clottability, stops
the expansion and growth of existing thrombi, prevents
formation of new thrombi and allows time for the body’s
normal thrombolysis mechanism to resolve existing
thrombi. Inthe absence of vitaminK1 thereis a substantial
decrease of active vitamin K- dependent factors in blood,
and a high risk for bleeding (factors II, VII, IX, X) and
thrombosis (protein C, protein S) [2]. Protein C and
protein S deficiencies are listed under “thrombophilia”,a
term applied to acquired and inherited abnormalities with
increased risk for thrombosis. Protein C is the vitamin
K-dependent precursor of an anticoagulant enzyme
activated protein C (APC). APC aided by protein S
markedly decreases the velocity of prothrombin conver-
sion to thrombin by degrading the procoagulant activities
of factors V and VIII. Coumadin administration causes
decreased protein C activity and a variably normal to
decreased antigen protein C concentration, with results
that can be misinterpreted as a protein C thrombophilia. If
protein C must be assessed while a patient is on Coum-
adintherapy, levels of protein C activitymust becompared
to that of prothrombin, factors VII, IX and X and a discre-
pancy indicating lower protein C activity than expected,
strongly suggests a protein C deficiency [3].
Risks of thrombosis and the risk of recurrence of
thrombosis differ among the coagulation defects asso-
ciated with inherited thrombophilia. Higher risks for
thrombosis were identified for subjects with antithrombin
(risk ratio 8.1, 95% confidence interval [CI], 3.4 to 19.6),
protein C (7.3, 95% CI, 2.9 to 18.4) or protein S deficiency
(8.5, 95% CI, 3. 5 to 20.8), and factor V Leiden (2.2, 95%
CI, 1.1 to 4.7) than for individuals with normal coagula-
tion [4]. The most frequent venous thrombotic manifesta-
tion was deep vein thrombosis with or without pulmonary
embolism (90% in antithrombin, 88% in protein C, 100%
in protein S deficiency, and 57% in factor V Leiden), but a
relatively mild manifestation such as superficial vein
thrombosis was common in factor V Leiden (43%). The
thrombosis risk is compounded by other heterozygous
mutations or in association with a chronic disorder, with
pregnancy, surgery or trauma. Deficiencies of both protein
C and protein S make up 2.5-5% of all persons with initial
deep vein thrombosis (DVT) and individuals with protein
C deficiency have a 6.5-increased relative risk of initial
DVT. Patients with heterozygous protein C deficiency have
an incidence of spontaneous thrombosis of approximately
0.4-2.5% per year. Approximately 50-70% of thromboses
are spontaneous. By the fifth decade, approximately 50%
of patients with heterozygous protein C and protein S
deficiency have experienced a thromboembolic event.
Case presentation
In July 2008, a 50 year-old white male was referred to us
for evaluation of the decision by his primary care
physician to maintain him on life-long anticoagulation,
a decision based on the findings of deficiencies of both
protein C and protein S. He is in good health and has no
known family history of DVT or coagulation abnormal-
ities. In June 2006, he fell from a tree at work, and a
fracture of his right femur was redressed by insertion of a
titanium rod. One week after surgery, he complained of
pain in his right calf. DVT was confirmed by Doppler
ultrasonography and he was anticoagulated with heparin
and Coumadin and maintained on 9 mg Coumadin and
325 mg aspirin until June 2007 when he began noticing
spontaneous bruising and large hematoma appearing
without provocation. He requested that his primary care
physician re-evaluate the basis for his anticoagulation.
Blood drawn while he was taking a therapeutic Coumadin
dose was sent to a regional laboratory for a thrombophilia
work up. Results of laboratory tests were significant for
protein S activity levels 36% [normal range 54-130%] and
protein C activity levels 10% [normal range 70-130%].
Protein C and protein S antigen levels were not performed,
and the test results were interpreted as a protein C and
protein S deficiency. In our laboratory we drew a blood
sample while the patient was taking Coumadin and we
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results shown in Table 1. We report a normal coagulation
profile and normal response to the prescribed Coumadin
dose, with no evidence of thrombophilia. There was no
evidence of elevated fibrinogen levels or abnormal
fibrinogen variants. Antithrombin levels were 100% as
would be anticipated in a patient on Coumadin for such a
long period of time. Protein C and protein S were within
range expected for the degree of anticoagulation. He was
returned to his primary care physician with recommenda-
tion that, although he did not have a protein C or protein S
deficiency he should remain on Coumadin until resolu-
tion of the venous obstruction that occurred consequent to
the surgery is confirmed by Doppler ultrasonography. In a
healthy male with a first DVT occurring after surgery or
trauma, the calculated risk of DVT recurrence is 0.27 very
low [5]. It is estimated that 10% of recurrences occur at
2 years and 23% at 5 years post anticoagulation therapy
[6]. Unresolved DVT may lead to post-phlebitic syndrome
and to a 2.6% annual, 12.4% at 5 years and 16.5% at
7 years increased risk of recurrent DVT [7].
Oral anticoagulation was discontinued based on a clotting
profile negative for thrombophilia and Doppler ultra-
sonography pattern consistent with normal blood flow in
the deep veins of the right calf and thigh predicting a
minimal calculated risk for DVT recurrence.
Conclusion
It is well established that the duration of Coumadin
treatment, three to six months or life-long, should be
based on the individual risk for recurrent DVT and on
the associated increased risk for bleeding complications
[7,8]. Furthermore, knowledge of Coumadin mechanism
of action and laboratory monitoring of Coumadin
therapy are essential to guide the clinical management
of DVT [2]. If protein C must be assessed while a patient
is on Coumadin therapy, levels of protein C activity
must be compared to those of prothrombin, factors VII,
IX and X and a discrepancy indicating lower protein C
activity than expected, strongly suggests a protein C
deficiency.
Much like thrombophilia, an unresolved DVT has an
equally high estimated risk for recurrence of DVT. In a
review article published in 2008 by Agnelli and colleagues,
the authors cite that a number of studies identify male
gender as a risk factor for recurrent DVT [9], a finding
first reported in a prospective observational study of
826 patients followed for an average of 36 months.
Venous thromboembolism (VTE) recurred in 33 out of
273 men (20%) in comparison with 28 out of 453 women
(6%) (RR 3.6. 95% CI 2.3-5.5). Furthermore, they report
that residual thrombosis has also been investigated as a
risk factor for recurrent VTE. A prospective cohort study
was performed to determine the risk for recurrent VTE
in patients who have persistent residual thrombosis
compared with patients who have early vein re-canaliza-
tion at the end of a conventional oral anticoagulant
treatment. The cumulative incidence of normal results at
Doppler ultrasonography was 38.8% at 6 months, 58.1%
at 12 months, 69.3% at 24 months, and 73.8% at
36 months. The hazard ratio for recurrent thromboembo-
lism was 2.4 (95% CI, 1.3-4.4; P = 0.004) for patients with
persistent residual thrombosis versus those with vein re-
canalization. The authors conclude that residual venous
thrombosis is a risk factor for recurrent VTE. This is the
basis for recommending Doppler ultrasonography to rule
out the potential of an unresolved DVT [9]. DVT
(intravascular obstruction of blood flow) is suspected
but cannot be confirmed nor diagnosed by clinical
symptoms. The diagnosis of DVT is not by laboratory
testing; laboratory testing provides an estimate of risks for
DVT recurrence and laboratory testing guides the duration
of anticoagulant management. Diagnosis of DVT is
obtained exclusively by imaging [10].
Table 1. Results of coagulation studies
Test Result Normal Range Control
Prothrombin Time (PT) 19.7 s 10-12.8 s 11.4 s
Activated Partial Thromboplastin Time (APTT) 36.5 s 20-30 s 26.4 s
Thrombin Clottable Fibrinogen 2.5 g/L 2-4 g/L
Heat Precipitable Fibrinogen Measured by Lowry’s Chemical Assay 2.5 g/L 2-4 g/L
Mixing studies with equal volume pooled normal plasma Corrects PT and APTT
Variant Fibrinogen Absent
Factor II activity 18%
1 80-100%
Factor VII activity 9%
1 80-100%
Factor X activity 18%
1 80-100%
Antithrombin II heparin cofactor activity 100% 70-100%
Antithrombin III immunoreactive protein 100% 70-100%
Protein C activity (inactivation of FV & FVIII) 76%
1 60-100%
Protein C immunoreactive levels 86%
1 60-100%
Protein S immunoreactive free levels 62%
1 60-100%
1Within expected range for degree of anticoagulation.
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